We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Medincell SA | EU:MEDCL | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.30 | 2.42% | 12.70 | 12.66 | 12.72 | 12.76 | 12.48 | 12.48 | 12,362 | 08:25:20 |
From Apr 2019 to Apr 2024
By Michael Dabaie
Teva Pharmaceuticals Industries Ltd. and MedinCell on Thursday said results were positive for Phase 3 clinical trial of TV-46000/mdc-IRM as a treatment for patients with schizophrenia.
Trial enrollment was open to patients 13-65 years of age. In the RISE study, patients treated with the investigational subcutaneous risperidone injection either monthly or once every two months experienced a statistically significant delay in time to relapse versus placebo, the study's primary objective.
No new safety signals have been identified that are inconsistent with the known safety profile of other risperidone formulations.
Teva will continue to lead the clinical development and regulatory process and be responsible for commercialization of this candidate treatment, with MedinCell eligible for development milestones, royalties on net sales and future commercial milestones.
Teva shares were up 0.7%, to $11.17, premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 07, 2021 08:57 ET (13:57 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Medincell Chart |
1 Month Medincell Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
